https://t.co/Mw7tfzMrfr

Half of children and young adolescents with tuberculosis are not diagnosed and therefore do not receive lifesaving treatment… but why? Take a look at the causes of this deadly gap, which we’ll be discussing in next week’s panel discussion. https://t.co/ggf8XyeLdf

Every child withTB deserves a healthy childhood. Yet in 2023, 1.25M fell ill with TB and nearly half were never diagnosed, thus never treated. Join our webinar moderated by @johngreen where survivors and treatment providers will discuss how to close these deadly gaps.

"Antibiogo was developed in collaboration with the people and countries that need it." We spoke on Antibiogo last week at the World Health Summit, sharing how it was developed by, for, and with the countries where we work. https://t.co/dQwkFICsPN #Innovation #WHS2025

🦠 It's estimated that by 2050, antibiotic resistance will cause 8.22 million deaths per year. To try and combat this, MSF launched Antibiogo, a free diagnostic aid app to combat antibiotic resistance by improving access to patient diagnoses. Learn more:

➡️ @Saludporderecho reports that in Spain the public price of WHO recommended six-month treatment BPaLM regimen is priced at €58,000. In contrast, LMICs can access the same regimen for less than €250. https://t.co/AMJgpKx1dk

💊Patents, trade policy, and why people's access to the medicines they need is at stake. @johnroshanj on India’s Free Trade Agreements with high-income countries, how they could mean higher medicine prices around the world, and why transparency in their negotiation matters.

When Johnson & Johnson tried to extend its patent monopoly on a lifesaving TB drug @MSF's Candice Andisiwe Sehoma sent TB survivor Phumeza Tisile to India to challenge it. It resulted in a 40% price drop for SA.

In the past 3 years, Poland has taken steps to improve TB treatment access by aligning national policies with WHO recommendations. But, many EU & EEA countries have not updated their guidelines and continue to grapple with barriers in accessing effective medicines and treatment.

Olga*, a person living with DR-TB in Warsaw, was started on the all-oral, six-month DR-TB regimen as recommended by the WHO to replace the previous DR-TB treatment regimen which was less effective and more toxic.

MSF first witnessed the systemic gaps in access to WHO-recommended #tuberculosis treatments in 2022 when we launched a response in Poland to assist Ukrainian refugees and other migrants in accessing tuberculosis treatment. A TB survivor shared her experience 🧵

At a panel discussion yesterday in Brussels, we urged policymakers, parliamentarians, regulatory agencies, and procurement bodies in the EU and the EEA to take urgent steps to bridge the gap in accessing tuberculosis treatment in the region. https://t.co/mRYOa47UAO

⏰ Tomorrow! Don’t miss our panel on improving access to TB medicines in EU/EEA. People with TB still face barriers to effective treatment & prevention, let's discuss solutions. Register Now👉 https://t.co/adSFpIsbMB

People with TB in EU and EEA still face limited access to effective treatment and prevention medicines. How can we fix that? On 14 Oct, join our panel discussion on how to improve the availability and affordability of TB medicines in the region. Register https://t.co/adSFpIsbMB

Ahead of the WHO Eastern Mediterranean Regional Committee, MSF shared challenges in addressing antimicrobial resistance in fragile & conflict settings, where it's critical to measure access gaps & improve availability of diagnostics & antibiotics. https://t.co/LAb25Fx8vy

While most countries agreed to the UN HLM Declaration on prevention & control of NCDs & mental health, it was not adopted. We urge countries to adopt the Declaration as it stands at the earliest opportunity & act to ensure equitable & affordable access to medical tools for all.

We welcome the agreement to provide ground-breaking HIV prevention drug at $40 in 2027, but global plans need to prioritise key populations and include the low- and middle-income countries to ensure sustainable access for all who need it. https://t.co/6lwEZi3MsF

Governments must agree on the most ambitious and concretely actionable political declaration to ensure access to insulin and diabetes care to all who need it, including during emergencies and in humanitarian settings. https://t.co/fApFxXHvoa

More than 800 million people have diabetes, the majority of whom live in low- and middle-income countries. For people with type 1 diabetes, insulin is lifesaving, but it is often unavailable in low-resource and emergency settings, and unaffordable elsewhere.

⏰ Tomorrow, governments will gather at the United Nations High Level Meeting (UN HLM) in New York to agree to a political declaration that will guide them on how to prevent and control noncommunicable diseases (NCDs) – including diabetes – and mental health until 2030. 🧵